Advanced and Recurrent Endometrial Cancer Treatments

Mismatch Repair Deficient (dMMR) Cancer

A critical biomarker in endometrial cancer is the mismatch repair (MMR) status. Patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumors often respond exceptionally well to immunotherapy.

• Durvalumab: This immunotherapy agent is a key component in treating dMMR primary advanced or recurrent endometrial cancer. It is frequently used in combination with platinum-based chemotherapy, specifically carboplatin and paclitaxel.
• Maintenance Therapy: Following initial treatment, maintenance strategies involving durvalumab, sometimes combined with olaparib, are recognized to sustain response in eligible patients.

Uterine Serous Carcinomas and HER2/neu

Uterine serous carcinomas are high-grade malignancies that require aggressive management. A specific subset of these tumors exhibits HER2/neu overexpression.

• Trastuzumab: For patients with HER2-positive disease, trastuzumab is utilized to target the HER2 pathway. It is often studied in combination with the chemotherapy backbone of carboplatin and paclitaxel.
• Carcinosarcoma: In the context of carcinosarcoma, HER2 testing is specifically recommended for advanced or metastatic disease.

Systemic Chemotherapy and Anti-Angiogenic Agents

Despite the rise of targeted therapies, platinum-based chemotherapy remains the "backbone" of treatment for many advanced-stage protocols.

Standard Chemotherapy Regimens

The most common regimens involve:

1. Carboplatin and Paclitaxel: Often the first-line choice for advanced disease.
2. Carboplatin and Docetaxel: An alternative platinum-based combination.

Bevacizumab

Bevacizumab is an anti-angiogenic agent that works by inhibiting the growth of new blood vessels that tumors need to survive. It has been investigated in clinical trials for managing recurrent or persistent endometrial cancer, frequently used in combination with paclitaxel and carboplatin.

Radiotherapy and Combined Modalities

For patients with high-risk disease or locoregional spread, radiation therapy is used to achieve local control.

• Whole Abdominopelvic Irradiation: This is employed for high-risk endometrial carcinoma to manage potential spread within the abdominal and pelvic cavities.
• Concurrent Chemoradiation: This involves the simultaneous administration of chemotherapy and radiation to exploit synergistic effects, improving outcomes in high-risk cases.
• Sandwich Therapy: A specialized sequential approach where chemotherapy is administered either before or after radiotherapy to maximize both local and systemic control.

Exam Tip: If a question asks about the management of Stage III-IV tumors with measurable disease, remember that the preferred systemic approach often involves a combination of platinum-based chemotherapy and an anti-angiogenic agent like Bevacizumab.

Summary of Treatment Selection

The selection of a treatment plan is not arbitrary; it is a calculated decision based on several variables:

$\text{Treatment Strategy} = f(\text{FIGO Stage, Biomarkers, Prior Treatment, Histology})$

Clinicians must weigh the FIGO stage (e.g., Stage III vs. IV), the presence of positive lymph nodes, and molecular markers such as mismatch repair status and HER2/neu expression to tailor the most effective regimen for the individual patient.